Clinical Trial Update: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers [Phase 1]

View source ↗

Summary

Terminated Phase 1 study evaluating CC-95251, a monoclonal antibody against SIRPα, in participants with advanced solid and hematologic cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CC-95251

Snippet

Sponsor: Celgene | Conditions: Neoplasms | Phase 1 | Status: TERMINATED